Altimmune (ALT) is advancing pemvidutide, a dual GLP-1/glucagon agonist, into a pivotal Phase 3 MASH trial in 2026.
Xenon Pharmaceuticals (XENE) stock soared 40% after Phase 3 trial data for azetukalner exceeded expectations in focal onset seizures. FDA filing set for Q3 2026.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果